Clinical trial
The Immunogenicity, Safety, and Effectiveness of the SARS-CoV-2 Vaccine (Vero Cell) Inactivated in Adult Population Aged 18 Years Old and Above in Indonesia
NCT05126550 is registered in ClinicalTrials.gov with PT. Kimia Farma (Persero) Tbk as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Immunogenicity, Safety, and Effectiveness of the SARS-CoV-2 Vaccine (Vero Cell) Inactivated in Adult Population Aged 18 Years Old and Above in Indonesia
- Lead sponsor
- PT. Kimia Farma (Persero) Tbk
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- November 13, 2021
- Completion date
- November 30, 2022
- Enrollment
- 435 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.